Drugs by condition
Drugs approved for prostate cancer
Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
58
Still marketed, NDA or BLA
Drug classes
9
Novel drugs
21
New molecular entities and new biologics
In development
40+
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for prostate cancer.
- Pylarify Truvu (Piflufolastat F-18) · Aphelion Mar 6, 2026
- Boncresa (Denosumab-Mobz) · Amneal Pharms LLC Dec 19, 2025
- Denosumab-Dssb (Denosumab-Dssb) · Samsung Bioepis CO LTD Oct 29, 2025
- Osvyrti (Denosumab-Desu) · Accord Biopharma Inc. Oct 29, 2025
- Enoby (Denosumab-Qbde) · Hikma Pharmaceuticals USA INC Sep 26, 2025
All approved drugs for prostate cancer, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 56 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
RANK Ligand Inhibitor (10)
- Prolia Denosumab · Amgen · 2010
- Boncresa Denosumab-Mobz · Amneal Pharms LLC · 2025
- Denosumab-Dssb Denosumab-Dssb · Samsung Bioepis CO LTD · 2025
- Osvyrti Denosumab-Desu · Accord Biopharma Inc. · 2025
- Enoby Denosumab-Qbde · Hikma Pharmaceuticals USA INC · 2025
- Aukelso Denosumab-Kyqq · Biocon Biologics INC · 2025
- Bilprevda Denosumab-Nxxp · Shanghai Henlius Biotech · 2025
- Conexxence Denosumab-Bnht · Fresenius Kabi USA LLC · 2025
- Osenvelt Denosumab-Bmwo · Celltrion INC · 2025
- Jubbonti Denosumab-Bbdz · Sandoz INC · 2024
Radioactive Diagnostic Agent (7)
- Posluma Flotufolastat F-18 Gallium · Blue Earth · 2023
- Pylarify Piflufolastat F-18 · Progenics Pharms INC · 2021
- Gallium Ga 68 Gozetotide Gallium Ga-68 Gozetotide · Univ Ca Los Angeles · 2020
- Gallium Ga 68 Gozetotide Gallium Ga-68 Gozetotide · Univ Of Ca San Fran · 2020
- Axumin Fluciclovine F-18 · Blue Earth · 2016
- Choline C-11 Choline C-11 · Mcprf · 2012
- Pylarify Truvu Piflufolastat F-18 · Aphelion · 2026
Microtubule Inhibitor (3)
Androgen Receptor Inhibitor (2)
5-alpha Reductase Inhibitor (2)
Radioligand Therapeutic Agent (1)
- Pluvicto Lutetium Lu-177 Vipivotide Tetraxetan · Novartis · 2022
Gonadotropin Releasing Hormone Receptor Antagonist (1)
- Orgovyx Relugolix · Sumitomo Pharma Am · 2020
Poly(ADP-Ribose) Polymerase Inhibitor (1)
- Lynparza Olaparib · Astrazeneca · 2017
Class not listed in FDA's data (31)
- Truqap Capivasertib · Astrazeneca · 2023
- Nubeqa Darolutamide · Bayer Healthcare · 2019
- Erleada Apalutamide · Janssen Biotech · 2018
- Rubraca Rucaparib Camsylate · Pharmaand · 2016
- Xofigo Radium Ra-223 Dichloride · Bayer Hlthcare · 2013
- Zytiga Abiraterone Acetate · Janssen Biotech · 2011
- Jevtana Kit Cabazitaxel · Sanofi Aventis US · 2010
- Firmagon Degarelix Acetate · Ferring · 2008
- Trelstar Triptorelin Pamoate · Verity · 2000
- Taxotere Docetaxel · Sanofi Aventis US · 1996
- Camcevi Etm Leuprolide Mesylate · Accord · 2025
- Gozellix Gallium Ga-68 Gozetotide · Telix Innovations · 2025
- Talzenna Talazoparib Tosylate · Pfizer · 2024
- Akeega Abiraterone Acetate, Niraparib Tosylate · Janssen Biotech · 2023
- Docetaxel Docetaxel · Avyxa Holdings · 2022
- Locametz Gallium Ga-68 Gozetotide · Novartis · 2022
- Illuccix Gallium Ga-68 Gozetotide · Telix · 2021
- Camcevi Kit Leuprolide Mesylate · Accord · 2021
- Leuprolide Acetate For Depot Suspension Leuprolide Acetate · Invagen Pharms · 2018
- Yonsa Abiraterone Acetate · Sun Pharm · 2018
- Zoledronic Acid Zoledronic Acid · Inforlife · 2013
- Docetaxel Docetaxel · Actavis · 2013
- Docetaxel Docetaxel · Sandoz · 2011
- Trelstar Triptorelin Pamoate · Verity · 2010
- Eligard Kit Leuprolide Acetate · Tolmar · 2004
- Eligard Kit Leuprolide Acetate · Tolmar · 2003
- Eligard Kit Leuprolide Acetate · Tolmar · 2002
- Eligard Kit Leuprolide Acetate · Tolmar · 2002
- Trelstar Triptorelin Pamoate · Verity · 2001
- Lupron Depot Leuprolide Acetate · Abbvie Endocrine INC · 1995
- Lupron Depot Leuprolide Acetate · Abbvie Endocrine INC · 1989
Drugs in development for prostate cancer
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
- ZG006Phase 38 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Neuroendocrine Carcinoma, Small Cell Lung Cancer, Solid Tumor
- OpevesostatMK-5684, ODM-208Phase 37 trials
Merck & Co. · Prostate Cancer Metastatic, Malignant Neoplasm, Metastatic Castration-resistant Prostate Cancer (mCRPC)
- XNW5004EZH2iPhase 37 trials
Evopoint Biosciences Inc. · Relapsed/Refractory Peripheral T Cell Lymphoma, Advanced Prostate Cancer, Follicular Lymphoma, Grade 1
- tinengotinibTT-00420Phase 36 trials
TransThera Sciences (Nanjing), Inc. · Prostate Cancer (CRPC), Cholangiocarcinoma, Hepatocellular Carcinoma (HCC)
- aglatimagene besadenovecCAN-2409, AdV-tkPhase 35 trials
Candel Therapeutics, Inc. · Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
- ONC-392Gotistobart, BNT316Phase 35 trials
OncoC4, Inc. · Non Small Cell Lung Cancer, Ovarian Cancer, Advanced Solid Tumor
- DB-1311BNT324Phase 34 trials
BioNTech SE · Metastatic Castration-resistant Prostate Cancer, Advanced Lung Cancer, Solid Tumors
- PasritamigJNJ-78278343Phase 34 trials
Johnson & Johnson (Janssen) · Solid Tumor, Metastatic Castration-resistant Prostatic Neoplasms, Metastatic Castration-resistant Prostate Cancer (mCRPC)
- 177Lu-PSMA-617Lutetium [177Lu] vipivotide tetraxetan, lutetium vipivotide tetraxetanPhase 33 trials
Novartis · Prostatic Neoplasms, Prostatic Neoplasm, Metastatic Castration Resistant Prostate Cancer (mCRPC)
- 64Cu-SAR-bisPSMAPhase 33 trials
Clarity Pharmaceuticals Ltd · Prostate Cancer, Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms
- CyclophosphamidPhase 33 trials
Alentis Therapeutics AG · Glomerulonephritis Rapidly Progressive, Diffuse Large B-Cell Lymphoma (DLBCL), Metastatic Colorectal Cancer
- Leuprorelin acetateLeuprolide Open Label, DKF-MA102Phase 33 trials
Pfizer · Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
- MevrometostatPF-06821497Phase 33 trials
Pfizer · Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer
2 discontinued brand-name drugs whose label still names it
More on prostate cancer: recruiting trials · published research
Related in oncology: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Melanoma · Ovarian cancer · Pancreatic cancer · Bladder and urothelial cancer · Kidney cancer (renal cell carcinoma) · Liver cancer (hepatocellular carcinoma)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.